August 5, 2021 US coronavirus news

By Meg Wagner, Melissa Mahtani, Veronica Rocha and Fernando Alfonso III, CNN

Updated 0158 GMT (0958 HKT) August 6, 2021
3 Posts
Sort byDropdown arrow
10:09 a.m. ET, August 5, 2021

There could be another variant worse than Delta if Covid-19 continues to spread, Fauci says

 From CNN’s Naomi Thomas

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks at a hearing in Washington, DC, on May 11, 2021.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks at a hearing in Washington, DC, on May 11, 2021. Greg Nash/Pool/Getty Images

If good control over community spread of the coronavirus isn’t achieved, and more people don’t get vaccinated, then it’s possible that there may be another variant that is worse than Delta, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told ABC’s George Stephanopoulos on Good Morning America, Thursday. 

“That will happen, George, if we don’t get good control over the community spread,” Fauci said when asked if the US is facing a continuous cycle of seeing new variants. 

“And as long as the virus continues to spread, you give it ample opportunity to mutate, and when you give it ample opportunity to mutate, you may sooner or later get another variant, and it is possible that that variant might be in some respects worse than the already very difficult variant we’re dealing with now,” he said. “Which is a major reason why you want to completely suppress the circulation of the virus in the community.” 

This is why he and his colleagues keep saying how important it is to get as many people as possible vaccinated. 

“People who say, I don’t want to get vaccinated because it’s me and I’ll worry about me, I’m not having any impact on anybody else, that’s just not the case,” he said. “Because when people don’t get vaccinated, it allows the virus to circulate through the community, and when it does, even if it doesn’t make a particular individual ill, they may be asymptomatic, that person is still a vehicle for the spread to other people.”

8:23 a.m. ET, August 5, 2021

WHO: Coronavirus-related deaths in Africa reach record peak

From CNN's Hannah Ritchie and Sharon Braithwaite

Coronavirus-related deaths in Africa reached a record peak in the week ending Aug. 1, according to data from the World Health Organization (WHO). 

Over 64,00 deaths were recorded across Africa, a 2% rise compared with the previous week, the WHO said in a news release Thursday. South Africa and Tunisia accounted for over 55% of the fatalities, but death trends are now on the rise in 15 African nations, the WHO found.  

With over 172,000 deaths recorded, Africa now accounts for roughly 4% of all Covid-19 fatalities globally. 

“It’s a sad day for Africa. Our hearts go out to everyone who has lost friends and loved ones. Deaths have peaked week-on-week on the continent and after a slight dip, COVID-19 cases are surging again. The latest data tells us that Africa is still on the crest of the third wave,” Dr Phionah Atuhebwe, New Vaccines Introduction Officer at WHO Africa said in a statement.

At least 22 African countries have seen coronavirus cases rise for the last two weeks, according to the WHO, and continent-wide infections rose by 19% in the week ending Aug. 1, with 278,000 new cases recorded. 

Africa currently has the slowest vaccine rollout in the world, with less than 2% of people across the continent fully vaccinated. 

10:20 a.m. ET, August 5, 2021

Moderna expects to complete submission for FDA full approval this month

From CNN's Naomi Thomas

Vials of the Moderna Covid-19 vaccine are in Reading, Pennsylvania, on April 1, 2021.
Vials of the Moderna Covid-19 vaccine are in Reading, Pennsylvania, on April 1, 2021. Ben Hasty/MediaNews Group/Reading Eagle/Getty Images

Moderna’s Covid-19 vaccine shows 93% efficacy through six months, and the company expects to complete its application for full US Food and Drug Administration approval this month, it said in a news release Thursday.

 “In final analysis of Phase 3 COVE study data, the Moderna COVID-19 Vaccine showed 93% efficacy, with the efficacy remaining durable through six months after administration of the second dose,” the news release said.

“Moderna has initiated the rolling submission process for a Biologics License Application (BLA) for our vaccine in the U.S. and expects to complete its submission in August.”

Moderna initiated its rolling submission for a BLA on June 1.

The data reflecting 93% efficacy reflected participants who had been fully vaccinated by Nov. 2020 and evaluated again four to six months later, prior to the current surge of Delta related cases in the US.

“I am proud of the progress our teams at Moderna have made in the past quarter in advancing our development pipeline while addressing a global pandemic and quickly establishing global manufacturing and commercial organizations,” Moderna CEO Stéphane Bancel said in the news release. “We now have mRNA candidates in clinical trials across five therapeutic areas including infectious diseases, cardiovascular, oncology, rare disease and autoimmune disorders. We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant.”